Adjuvant Action of Melittin Following Intranasal Immunisation with Tetanus and Diphtheria Toxoids

Abstract

Melittin, a 26-amino acid peptide and the major active component of the venom of the honey bee—Apis mellifera—has recently been shown to have absorption enhancing properties in Caco-2 cells at levels well below the level required for the generation of cytotoxicity. Given the potential of absorption enhancing agents to act as adjuvants when administered nasally [Alpar, H.O., Eyles, J.E., Williamson, E.D. and Somavarapu, S. (2001) “Intranasal vaccination against plague, tetanus and diphtheria”, Adv. Drug Delivery Rev. 51, 173–201] we hypothesized that melittin may have potential as a mucosal adjuvant. Following our initial studies reported here, it was found that the co-administration of 4 μg of melittin in conjunction with tetanus toxoid in BALB/c mice was effective in eliciting markedly enhanced antibody titres in comparison to control groups and groups receiving free antigen administered intranasally. Lower concentrations of melittin were less effective and mice receiving 4 μg of melittin plus antigen exhibited antibody titres significantly higher (i.e. P<0.05) than any of the other groups tested. The observed IgG2a titres were shown to be dependent upon the dose of melittin co-administered with the immunising antigen in a similar fashion to the observed total IgG responses. In summary, melittin has been shown here to have potential as a novel mucosal adjuvant for antigens administered via the nasal route.

Keywords::

• Melittin
• Mucosal Adjuvant
• Nasal
• Vaccine
• Absorption enhancer